As the research community races to identify safe and effective COVID-19 therapies, researchers are in need of accelerating trial design without sacrificing quality. The Clinical Trials Transformation Initiative (CTTI) will discuss designing high-quality COVID-19 treatment trials via a webinar Thursday, April 23 at 9:30 ET.

Speakers will include:

• Janet Woodcock, FDA, CDER
• Ed Cox, Regeneron Pharmaceuticals, Inc.
• Martin Landray, University of Oxford
• John Marshall, WHO Clinical Characterization and Management Working Group, Unity Health CA
• Karlin Schroeder, Parkinson’s Foundation
• Fergus Sweeney, European Medicines Agency
• Ann Meeker O’Connell, Vertex Pharmaceuticals

During the webinar, COVID-19 researchers will glean best practices for designing trials that are streamlined, high-quality, and minimize burdens on front-line hospital staff and study participants.